• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Sight Sciences Inc.

    1/23/25 3:08:59 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Sight Sciences, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    82657M105

    (CUSIP Number)


    01/16/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    82657M105


    1Names of Reporting Persons

    LONG FOCUS CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,559,003.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,559,003.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,559,003.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    82657M105


    1Names of Reporting Persons

    LONG FOCUS CAPITAL MASTER, LTD.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,867,714.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,867,714.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,867,714.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    82657M105


    1Names of Reporting Persons

    CONDAGUA, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,289.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,289.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,289.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    82657M105


    1Names of Reporting Persons

    JOHN HELMERS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,559,003.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,559,003.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,559,003.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    82657M105


    1Names of Reporting Persons

    GLENN HELMERS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,289.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,289.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,289.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sight Sciences, Inc.
    (b)Address of issuer's principal executive offices:

    4040 Campbell Ave, Suite 100, Menlo Park, CA
    Item 2. 
    (a)Name of person filing:

    LONG FOCUS CAPITAL MANAGEMENT LLC LONG FOCUS CAPITAL MASTER, LTD. CONDAGUA, LLC JOHN HELMERS GLENN HELMERS
    (b)Address or principal business office or, if none, residence:

    207 CALLE DEL PARQUE A&M TOWER, 8TH FLOOR SAN JUAN, PR 00912
    (c)Citizenship:

    Long Focus Capital Management, LLC, a Delaware single member limited liability company; Long Focus Capital Master, LTD., a Cayman Islands limited company; Condagua, LLC, a Delaware single member limited liability company; John Helmers, a United States citizen; and Glenn Helmers, a United States citizen.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    82657M105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row (9) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 16, 2025. Long Focus Capital Management, LLC, John Helmers, and Glenn Helmers directly own no Common Stock. Pursuant to an investment management agreement, Long Focus Capital Management, LLC maintains investment and voting power with respect to the securities held by Long Focus Capital Master, Ltd. John Helmers controls Long Focus Capital Management, LLC and has investment and voting power with respect to Condagua, LLC. Glenn Helmers controls Condagua, LLC.
    (b)Percent of class:

    The information required by Item 4(b) is set forth in Row (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 16, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row (5) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 16, 2025.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row (6) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 16, 2025.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row (7) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 16, 2025.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row (8) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 16, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    (a) The following certification shall be included if the statement is filed pursuant to ??240.13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to LONG FOCUS CAPITAL MASTER, LTD., is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    LONG FOCUS CAPITAL MANAGEMENT, LLC
     
    Signature:/s/ John Helmers
    Name/Title:John Helmers/Managing Member
    Date:01/23/2025
     
    LONG FOCUS CAPITAL MASTER, LTD.
     
    Signature:/s/ John Helmers
    Name/Title:John Helmers/Managing Member
    Date:01/23/2025
     
    CONDAGUA, LLC
     
    Signature:/s/ Glenn Helmers
    Name/Title:Glenn Helmers/Managing Member
    Date:01/23/2025
     
    JOHN HELMERS
     
    Signature:/s/ John Helmers
    Name/Title:John Helmers
    Date:01/23/2025
     
    GLENN HELMERS
     
    Signature:/s/ Glenn Helmers
    Name/Title:Glenn Helmers
    Date:01/23/2025
    Get the next $SGHT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    8/8/2025$5.00Hold → Buy
    Lake Street
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences upgraded by Lake Street with a new price target

    Lake Street upgraded Sight Sciences from Hold to Buy and set a new price target of $5.00

    8/8/25 8:25:35 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on Sight Sciences with a new price target

    UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50

    12/6/24 8:14:13 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Encrantz Staffan bought $115,963 worth of shares (13,958 units at $8.31), increasing direct ownership by 1% to 1,391,922 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    12/18/25 6:10:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Director Encrantz Staffan bought $381,958 worth of shares (90,525 units at $4.22) and was granted 30,952 shares, increasing direct ownership by 10% to 1,377,964 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    6/6/25 9:10:58 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Director Encrantz Staffan bought $376,429 worth of shares (98,782 units at $3.81), increasing direct ownership by 9% to 1,256,487 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    6/3/25 9:57:16 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

    MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2025. Select Preliminary Financial Highlights Fourth quarter 2025 total revenue is expected to be in the range of $20.3 million to $20.4 million, an increase of 7% at the estimated midpoint compared to the prior year period. Surgical Glaucoma revenues are expected to be in the rang

    1/13/26 7:05:00 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans

    MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, announced today the results from three key published manuscripts that further demonstrate the value of an interventional mindset in treating glaucoma. "We are proud to continuously support the study of interventional glaucoma treatment, especially in highlighting critical groups of patients that may benefit from active surgical interventions. These results demonstrate that when surgeons are given the right solut

    11/11/25 7:00:00 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated third quarter 2025 total revenue of $19.9 million, a decrease of 1% compared to the same period in the prior year. The Company's Surgical Glaucoma revenue increased

    11/6/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Sight Sciences Inc.

    SCHEDULE 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    2/4/26 12:09:03 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    2/3/26 5:30:15 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    1/13/26 7:09:56 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Badawi David was granted 64,915 shares, increasing direct ownership by 3% to 1,977,188 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/5/26 4:49:56 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Bauerlein Alison was granted 127,512 shares, increasing direct ownership by 21% to 727,495 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/5/26 4:48:58 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Chief Legal Officer Hayden Jeremy B. was granted 115,920 shares, increasing direct ownership by 43% to 383,531 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/5/26 4:49:28 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Leadership Updates

    Live Leadership Updates

    View All

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Appoints Gary Burbach to its Board of Directors

    MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

    4/22/25 4:05:00 PM ET
    $BWXT
    $SGHT
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

    MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

    11/7/24 4:04:00 PM ET
    $INGN
    $SGHT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $SGHT
    Financials

    Live finance-specific insights

    View All

    Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated third quarter 2025 total revenue of $19.9 million, a decrease of 1% compared to the same period in the prior year. The Company's Surgical Glaucoma revenue increased

    11/6/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

    MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 6, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the even

    10/23/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated second quarter 2025 total revenue of $19.6 million, a decrease of 8% compared to the same period in the prior year. This expected decline was primarily due to low

    8/7/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    11/14/24 11:57:36 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    2/14/24 5:24:02 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sight Sciences Inc.

    SC 13G - Sight Sciences, Inc. (0001531177) (Subject)

    2/13/24 6:52:37 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care